Publications by authors named "A O Oladapo"
Methamphetamine is a widely abused drug associated with significant neuroinflammation and neurodegeneration, mainly through the activation of glial cells and neurons in the central nervous system. This study investigates the role of the astrocyte-specific NOD-like receptor family pyrin domain-containing protein 6 (NLRP6) inflammasome in methamphetamine-induced astrocytic pyroptosis and neuroinflammation. Our findings demonstrate that methamphetamine exposure induces NLRP6-dependent pyroptosis, astrocyte activation, and the release of proinflammatory cytokines in mouse primary astrocytes.
View Article and Find Full Text PDFMethamphetamine is a highly addictive stimulant known to cause neurotoxicity, cognitive deficits, and immune dysregulation in the brain. Despite significant research, the molecular mechanisms driving methamphetamine-induced neurotoxicity and glial cell dysfunction remain poorly understood. This study investigates how methamphetamine disrupts glial cell function and contributes to neurodevelopmental and neurodegenerative processes.
View Article and Find Full Text PDFAlcohol is the most abused substance among adolescents and has a profound impact on health, society, and the economy. Alcohol intoxication is linked to neuroinflammation and neuronal damage, which result in behavioral alterations such as motor dysfunction, neuronal injury, cognitive deficits, and inflammation. Alcohol-induced neuroinflammation is associated with the activation of central nervous system cells, including astrocytes, and the release of proinflammatory cytokines.
View Article and Find Full Text PDFArticle Synopsis
- Rheumatologic disease-associated hemophagocytic lymphohistiocytosis (HLH) is a rare and serious condition that may arise from underlying autoimmune diseases; real-world data on the use of the monoclonal antibody emapalumab for treatment is limited.
- A study called REAL-HLH reviewed medical records from 33 hospitals to evaluate the use and outcomes of emapalumab in patients with rheumatologic disease-associated HLH, finding that 14.3% of 105 patients studied had this subtype.
- Results showed that emapalumab treatment led to improvements in key laboratory parameters, significantly reduced glucocorticoid use, and had a high survival rate, indicating its potential effectiveness in managing
Introduction: Patients with chronic refractory gout face a considerable burden of disease due to unexpected flares characterized by severe and debilitating pain, which can lead to chronic pain and joint damage. This study aimed to understand the symptoms and impacts of chronic refractory gout on health-related quality of life (HRQoL).
Methods: A targeted literature review was conducted to identify and review key articles describing the symptoms and impacts of gout, and articles examining the psychometric performance of the Medical Outcomes Survey Short Form-36 (SF-36) and Health Assessment Questionnaire-Disability Index (HAQ-DI) in gout.